AbbVie touts long-term efficacy of Qulipta as preventive migraine treatment
AbbVie released interim Phase III data for its calcitonin gene-related peptide receptor blocker Qulipta (atogepant), which demonstrated long-term safety and efficacy for patients in preventing chronic and episodic migraine.